**MANAGEMENT TEAM**
Sam Tischfield, PhD, *Interim CEO*

**SCIENTIFIC FOUNDERS**
Olivier Elemento, PhD, WCM
Iman Hajirasouliha, PhD, WCM
Zev Rosenwaks, PhD, WCM
Nikica Zaninovic, PhD, WCM

**CONTACT**
sam.tischfield@gmail.com
imh2003@med.cornell.edu

**PARTNERS**
Ronald O. Perelman and Claudia Cohen Center for Reproductive Medicine at Weill Cornell Medicine

**TARGET RAISE:** $3-5M

**USE OF FUNDS:**
- FDA approval
- Product development
- Working capital

**ADVISORS**
Loren A. Busby, CFA, WCM EiR

## COMPANY

Stork.ai is leveraging its strong foundations in reproductive medicine, big data, and artificial intelligence to create next-generation fertility products that ultimately help people have babies. It is commercializing a decision assessment tool comprised of patent-pending, AI-based software ("STORK") that reliably assesses embryo (blastocyst) quality. STORK was developed using a proprietary, multi-focal embryo image dataset from Weill Cornell's Center for Reproductive Medicine. STORK can also predict genetic defects such as aneuploidy, which involves an abnormal number of chromosomes in the embryo.

## THE PROBLEM

In vitro fertilization (IVF) is a reliable service for couples who cannot get pregnant. IVF helps with fertilization, embryo development, and implantation. Although IVF and embryo-transfer technologies have improved considerably, the efficacy of IVF remains relatively low, about 32.7% on average by cycle. Furthermore, IVF remains prohibitively costly with the average cost of an IVF cycle in the U.S. at $12,400[1]. Conventional embryo evaluation involves manual grading of viability at a single time point. This process is incomplete, time-consuming and hampered by low inter-observer reliability where industry practices involve implanting multiple embryos in order to achieve a successful live birth. STORK applies deep learning techniques to improve the selection of a single best embryo with the highest implantation potential. Studies have shown that STORK's technology results in increased pregnancies while minimizing the need to transfer multiple embryos, which decreases the health risks for women.

## PLATFORM ADVANTAGES

STORK assesses blastocyst quality with a predictive accuracy of >98%, can be generalized to work on images from clinics outside the US, and outperforms individual embryologists. In addition, STORK incorporates maternal age and the quality of multiple embryos to determine the best combination to achieve a single live birth. The technology advantage is that instead of only focusing on the predetermined, segmented features that embryologists are trained to analyze, the entire image of the embryo is assessed, allowing for quantification of all the available data.

## MARKET

The company is addressing intractable problems in reproductive health which affect 186M people worldwide and ~8% of US women of child-bearing age.

## PRODUCT PIPELINE

- Blastocyst selection tool *(completed)*
- Aneuploidy detection *(completed)*
- Expanding aneuploidy detection capabilities *(ongoing)*
- Sperm grading *(ongoing)*
- Egg grading *(ongoing)*
- Further precision medicine algorithms for fertility *(ongoing)*

## INTELLECTUAL PROPERTY

The company filed a patent covering its method for classifying blastocysts. (WO2020033391A1; PCT/US2019/045283)

## COMPETITIVE LANDSCAPE

- Traditional grading methods
- Presagen
- VitroLife

---

[1] "Growth Insights on the US In Vitro Fertilization Services Market 2018," Frost & Sullivan, May 2019